Skye Bioscience, Inc.
SKYE
$2.23
$0.3518.62%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 15.94M | 15.98M | 15.80M | 16.93M | 17.66M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 48.65M | 59.08M | 58.16M | 55.62M | 51.87M |
| Operating Income | -48.65M | -59.08M | -58.16M | -55.62M | -51.87M |
| Income Before Tax | -50.49M | -57.33M | -55.92M | -51.22M | -42.37M |
| Income Tax Expenses | 3.40K | 3.40K | 5.40K | 5.40K | 5.40K |
| Earnings from Continuing Operations | -50.49 | -57.33 | -55.92 | -51.23 | -42.37 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -50.49M | -57.33M | -55.92M | -51.23M | -42.37M |
| EBIT | -48.65M | -59.08M | -58.16M | -55.62M | -51.87M |
| EBITDA | -47.96M | -58.36M | -57.44M | -54.90M | -51.27M |
| EPS Basic | -10.18 | -11.56 | -11.28 | -10.32 | -8.55 |
| Normalized Basic EPS | -6.01 | -7.27 | -7.09 | -6.70 | -6.18 |
| EPS Diluted | -10.22 | -11.60 | -11.28 | -10.32 | -8.55 |
| Normalized Diluted EPS | -6.01 | -7.27 | -7.09 | -6.70 | -6.18 |
| Average Basic Shares Outstanding | 19.84M | 19.84M | 19.83M | 19.87M | 19.76M |
| Average Diluted Shares Outstanding | 19.84M | 19.84M | 19.83M | 19.87M | 19.76M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |